To translate this therapy into the clinic is crucial to test the effectiveness of the combined treatment in a more advanced PD model, namely, rats with only 30% of tyrosine hydroxylase positive neurons (TH+) in the substantia nigra pars compacta (SNc) of both sides. The gene discussed is TH; the disease is Parkinson disease.